^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Selzentry (maraviroc) (CCR5 receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined PD-1 inhibition (Pembrolizumab) and CCR5 inhibition (Maraviroc) for the treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC): First results of the PICCASSO phase I trial.
Published date:
05/13/2020
Excerpt:
Therapy with pembrolizumab and maraviroc was feasible and showed a beneficial toxicity pattern. Clinical activity in MSS CRC patients was limited, however prolonged disease stabilizations were observed in single patients and overall survival was higher than expected in this heavily pretreated population.
DOI:
10.1200/JCO.2020.38.15_suppl.3010
Trial ID: